Early Access

Back to REGN

REGENERON PHARMACEUTICALS, INC. R&D Expense 2008-2025 | REGN

Beta

What is r&d expense?

Research and development expense represents the costs incurred in discovering and developing new products, processes, or technologies.

What is REGENERON PHARMACEUTICALS, INC.'s current r&d expense?

REGENERON PHARMACEUTICALS, INC. (REGN) annual r&d expense for 2025 was $5.85B, a 13.99% increase from 2024. REGENERON PHARMACEUTICALS, INC. r&d expense for the quarter ending December 31, 2025 was $1.63B.

What was REGENERON PHARMACEUTICALS, INC.'s r&d expense in 2024?

REGENERON PHARMACEUTICALS, INC. annual r&d expense for 2024 was $5.13B, a 15.61% increase from 2023.

What was REGENERON PHARMACEUTICALS, INC.'s r&d expense in 2023?

REGENERON PHARMACEUTICALS, INC. annual r&d expense for 2023 was $4.44B, a 23.56% increase from 2022.

What is REGENERON PHARMACEUTICALS, INC.'s 5-year r&d expense CAGR?

REGENERON PHARMACEUTICALS, INC. r&d expense grew at a compound annual growth rate (CAGR) of 17.19% from FY2020 to FY2025, going from $2.65B to $5.85B over 5 years.

R&D Expense History

Year-over-year comparison from 10-K annual reports

Key Statistics
Trend Direction
Growing
CAGR+17.2%
FY2020
$2.65B
FY2025
$5.85B
080910111213141516171819202122232425
5 years selected
R&D Expense History
PeriodValueChangeSource
FY2025$5.85B+14.0%10-K
FY2024$5.13B+15.6%10-K
FY2023$4.44B+23.6%10-K
FY2022$3.59B+25.6%10-K
FY2021$2.86B+8.1%10-K
FY2020$2.65B+8.0%10-K
FY2019$2.45B+66.8%10-K
FY2018$1.47B-29.2%10-K
FY2017$2.08B+1.1%10-K
FY2016$2.05B+26.6%10-K
FY2015$1.62B+27.5%10-K
FY2014$1.27B+47.8%10-K
FY2013$859.9M+37.5%10-K
FY2012$625.6M+18.1%10-K
FY2011$529.5M+8.2%10-K
FY2010$489.3M+22.7%10-K
FY2009$398.8M+45.1%10-K
FY2008$274.9M-10-K
Company: REGENERON PHARMACEUTICALS, INC.Ticker: REGNSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →